TG13 antimicrobial therapy for acute cholangitis and cholecystitis

详细信息    查看全文

• 作者：Harumi Gomi (1)
  Joseph S. Solomkin (2)
  Tadahiro Takada (3)
  Steven M. Strasberg (4)
  Henry A. Pitt (5)
  Masahiro Yoshida (6)
  Shinya Kusachi (7)
  Toshihiko Mayumi (8)
  Fumihiko Miura (3)
  Seiki Kiriyama (9)
  Masamichi Yokoe (10)
  Yasutoshi Kimura (11)
  Ryota Higuchi (12)
  John A. Windsor (13)
  Christos Dervenis (14)
  Kui-Hin Liau (15)
  Myung-Hwan Kim (16)
  
• 关键词：Acute cholangitis ; Acute cholecystitis ; Antimicrobial therapy ; Treatment guidelines ; Biliary tract infection
• 刊名：Journal of Hepato-Biliary-Pancreatic Sciences
• 出版年：2013
• 出版时间：January 2013
• 年：2013
• 卷：20
• 期：1
• 页码：60-70
• 全文大小：342KB
• 参考文献：1. van den Hazel SJ, Speelman P, Tytgat GNJ, Dankert J, van Leeuwen DJ. Role of antibiotics in the treatment and prevention of acute and recurrent cholangitis. Clin Infect Dis. 1994;19:279-6.
  2. Beoy JH, Way LW. Acute cholangitis. Ann Surg. 1980;191:264-0.
  3. Tanaka A, Takada T, Kawarada Y, Nimura Y, Yoshida M, Miura F, et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:59-7 (Clinical practice guidelines: CPGs).
  4. Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, et al. Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:83-0 (CPGs).
  5. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-27 (CPGs).
  6. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133-4 (CPGs).
  7. Paterson DL, Rossi F, Baquero F, Hsueh P-R, Woods GL, Satishchandran V, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother. 2005;55:965-3.
  8. Rossi F, Baquero F, Hsueh P-R, Paterson DL, Bochicchio GV, Snyder TA, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother. 2006;58:205-0.
  9. Yang Q, Wang H, Chen M, Ni Y, Yu Y, Hu B, et al. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-009 Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2010;36:507-2.
  10. Hsueh P-R, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents. 2010;36:408-4.
  11. Chen Y-H, Hsueh P-R, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect. 2011;62:280-1.
  12. Ishii Y, Tateda K, Yamaguchi K. Evaluation of antimicrobial susceptibility for β-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). Diagn Microbiol Infect Dis. 2008;60:177-3.
  13. Ishii Y, Ueda C, Kouyama Y, Tateda K, Yamaguchi K. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). Diagn Microbiol Infect Dis. 2011;69:443-.
  14. Sung YK, Lee JK, Lee KH, Lee KT, Kang C-I. The clinical epidemiology and outcomes of bacteremic biliary tract infections caused by antimicrobial-resistant pathogens. Am J Gastroenterol. 2012;107:473-3.
  15. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34 (5, Supplement):S20–S8.
  16. Choi SH, Lee J, Park S, Kim MN, Choo E, Kwak Y, et al. Prevalence, microbiology, and clinical characteristics of extended-spectrum; beta-lactamase-producing / Enterobacter spp., / Serratia marcescens, / Citrobacter freundii and / Morganella morganii in Korea. Eur J Clin Microb Infect Dis. 2007;26:557-1.
  17. Kang CI, Cheong H, Chung D, Peck K, Song JH, Oh MD, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing / Escherichia coli. Eur J Clin Microb Infect Dis. 2008;27:85-.
  18. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-02.
  19. Peirano G, van der Bij AK, Gregson DB, Pitout JDD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing / Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012;50:294-.
  20. Kune G, Schutz E. Bacteria in the biliary tract. A study of their frequency and type. Med J Aust. 1974;1:255-.
  21. Csendes A, Fernandez M, Uribe P. Bacteriology of the gallbladder bile in normal subjects. Am J Surg. 1975;129:629-1.
  22. Csendes A, Becerra M, Burdiles P, Demian I, Bancalari K, Csendes P. Bacteriological studies of bile from the gallbladder in patients with carcinoma of the gallbladder, cholelithiasis, common bile duct stones and no gallstones disease. Eur J Surg. 1994;160:363-.
  23. Csendes A, Burdiles P, Maluenda F, Diaz J, Csendes P, Mitru N. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg. 1996;131:389-4.
  24. Csendes A, Mitru N, Maluenda F, Diaz J, Burdiles P, Csendes P, Pinones E. Counts of bacteria and pyocites of choledochal bile in controls and in patients with gallstones or common bile duct stones with or without acute cholangitis. Hepatogastroenterology. 1996;43:800-.
  25. Maluenda F, Csendes A, Burdiles P, Diaz J. Bacteriological study of choledochal bile in patients with common bile duct stones, with or without acute suppurative cholangitis. Hepatogastroenterology. 1989;36:132-.
  26. Chang W, Lee K, Wang S, Chuang S, Kuo K, Chen J, Sheen P. Bacteriology and antimicrobial susceptibility in biliary tract disease: an audit of 10-year’s experience. Kaohsiung J Med Sci. 2002;18:221-.
  27. Salvador V, Lozada M, Consunji R. Microbiology and antibiotic susceptibility of organisms in bile cultures from patients with and without cholangitis at an Asian Academic Medical Center. Surg Infect. 2011;12:105-1.
  28. Kuo CH CC, Chen JJ, Tai DI, Chiou SS, Lee CM. Septic acute cholecystitis. Scand J Gastroenterol. 1995;30:272-
  29. Melzer M, Toner R, Lacey S, Bettany E, Rait G. Biliary tract infection and bacteremia: presentation, structural abnormalities, causative organisms and clinical outcomes. Postgrad Med J. 2007;83:773-.
  30. Lee C–C, Chang IJ, Lai Y-C, Chen S-Y, Chen S-C. Epidemiology and prognostic determinants of patients with bacteremic cholecystitis or cholangitis. Am J Gastroenterol. 2007;102:563-.
  31. Baitello AL, Colleoni Neto R, Herani Filho B, Cordeiro JA, Machado AMO, Godoy MF, et al. Prevalência e fatores associados à bacteremia nos portadores de colecistite aguda litiásica. Revista da Associa??o Médica Brasileira. 2004;50:373-.
  32. Kelly AM. Clinical impact of blood cultures taken in the emergency department. J Accid Emerg Med. 1998;15:254-.
  33. Brunton LL, Chabner BA, Knollman BC, editors. Goodman and Gilman’s the pharmacological basis of therapeutics, 12th edition. New York: The McGraw-Hill Companies; 2011.
  34. Amsden G. Chapter 49, Tables of antimicrobial agent pharmacology. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases, 7th edition, Volume 1. Philadelphia: Churchill Livingston, Elsevier; 2010. p. 705-1.
  35. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother. 2011;66 (suppl 2):ii25-1.
  36. Goldstein EJ, Solomkin JS, Citron DM, Alder JD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011;53:1074-0.
  37. Solomkin J, Zhao YP, Ma EL, Chen MJ, DRAGON Study Team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents. 2009;34:439-5.
  38. Weiss G, Reimnitz P, Hampel B, Muehlhofer E, AIDA Study Group. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother. 2009;21:170-0.
  39. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg. 2006;244:204-1.
  40. Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs. 2012;72:1-6.
  41. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28:1079-06.
  42. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on non-inferiority trials. Clin Infect Dis. 2012;54:1699-709.
  43. Muller E, Pitt HA, Thompson JE Jr, Doty J, Mann L, Manchester B. Antibiotics in infections of the biliary tract. Surg Gynecol Obstet. 1987;165:285-2.
  44. Gerecht W, Henry N, Hoffman W, Muller S, LaRusso N, Rosenblatt J, Wilson W. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med. 1989;149:1279-4.
  45. Thompson JE Jr, Pitt HA, Doty J, Coleman J, Irving C. Broad spectrum penicillin as an adequate therapy for acute cholangitis. Surg Gynecol Obstet. 1990;171:275-2.
  46. Chacon J, Criscuolo P, Kobata C, Ferraro J, Saad S, Reis C. Prospective randomized comparison of pefloxacin and ampicillin plus gentamicin in the treatment of bacteriologically proven biliary tract infections. J Antimicrob Chemother. 1990;26,Suppl B:167-2.
  47. Thompson JE Jr, Bennion R, Roettger R, Lally K, Hopkins J, Wilson SE. Cefepime for infections of the biliary tract. Surg Gynecol Obstet. 1993;177 Suppl:30-. discussion 35-0.
  48. Yellin AE, Berne TV, Appleman MD, Heseltine PN, Gill MA, Okamoto MP, Baker FJ, Holcomb C. A randomized?study?of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis. Surg Gynecol Obstet. 1993;177 Suppl:23-9; discussion 35-0.
  49. Sung J, Lyon D, Suen R, Chung S, Co A, Cheng A, Leung J, et al. Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. J Antimicrob Chemother. 1995;35:855-4.
  50. Powers JH. Editorial commentary: Asking the right questions: morbidity, mortality and measuring what’s important in unbiased evaluations of antimicrobials. Clin Infect Dis. 2012;54:1710-713.
  51. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-02.
  52. Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA. Centers for Disease Control and Prevention Epicenter Program. Emergence and rapid regional spread of / Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2011;53:532-0.
  53. Di Carlo P, Pantuso G, Cusimano A, D’Arpa F, Giammanco A, Gulotta G, Latteri AM, Madonia S, Salamone G, Mammina C. Two cases of monomicrobial intraabdominal abscesses due to KPC- / Klebsiella pneumoniae ST258 clone. BMC Gastroenterol. 2011;30(11):103.
  54. Bogdanovich T, Adams-Haduch JM, Tian GB, Nguyen MH, Kwak EJ, Muto CA, et al. Colistin-resistant, / Klebsiella pneumoniae carbapenemase (KPC)-producing / Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis. 2011;53:373-.
  55. Solomkin JS, Dellinger EP, Bohnen JM, Rostein OD. The role of oral antimicrobias for the management of intra-abdominal infections. New Horiz. 1998;Suppl 2:S46-2.
  56. Brand M, Bizs D, O’Farrell PJR. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography (review). Cochrane Database Syst Rev. 2010 Oct 6;(10):CD007345.
  57. Hirota WK, Petersen K, Baron TH, Goldstein JL, Jacobson BC, Leighton JA, et al. Guidelines for antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2003;58:475-2 (CPGs).
  58. Bai Y, Gao F, Gao J, Zou DW, Li ZS. Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography-induced cholangitis: meta-analysis. Pancreas. 2009;38:126-0.
  59. Branders JW, Scheffer B, Lorenz-Meyer H, Korst HA, Littmann KP. ERCP: complications and prophylaxis. A controlled study. Endoscopy. 1981;13:27-0.
  60. Byl B, Deviere J, Struelens MJ, Roucloux I, De Coninck A, Thys JP, et al. Antibiotic prophylaxis of infectious complications after therapeutic endoscopic retrograde cholangiopancreatography: a randomized, double-blind, placebo-controlled study. Clin Infect Dis. 1995;20:1236-0.
  61. Van den Hazel SJ, Speelman P, Dankert J, Huibregtse K, Tytgat GNJ, Van Leeuen DJ. Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. Ann Intern Med. 1996;125:442-.
  62. Llach J, Bordas JM, Almela M, Pellise M, Mata A, Soria M, et al. Prospective assessment of the role of antibiotic prophylaxis in ERCP. Hepatogastroenterology. 2006;53:540-.
  63. Lorenz R, Lehn N, Born P, Hermann M, Neuhaus H. Antibiotic prophylaxis with cefuroxime in therapeutic endoscopy of the bile ducts. Dtsch Med Wochenschr. 1996;121:223-0.
  64. Sauter G, Grabein B, Mannes GA, Reckdeschel G, Sauerbruch T. Antibiotic prophylaxis of infectious complications with endoscopic retrograde cholangiopancreatography. A randomized controlled study. Endoscopy. 1990;22:164-.
  65. Niederau C, Pohlmann U, Lubke H, Thomas L. Antibiotic prophylaxis during therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study. Gastrointest Endosc. 1994;40:533-.
  66. R?ty S, Sand J, Pulkkinen M, Matikainen M, Norback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg. 2001;5:339-5.
  67. Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. Ann Surg. 2011;253:1082-3 (CPGs).
  
• 作者单位：Harumi Gomi (1)
  Joseph S. Solomkin (2)
  Tadahiro Takada (3)
  Steven M. Strasberg (4)
  Henry A. Pitt (5)
  Masahiro Yoshida (6)
  Shinya Kusachi (7)
  Toshihiko Mayumi (8)
  Fumihiko Miura (3)
  Seiki Kiriyama (9)
  Masamichi Yokoe (10)
  Yasutoshi Kimura (11)
  Ryota Higuchi (12)
  John A. Windsor (13)
  Christos Dervenis (14)
  Kui-Hin Liau (15)
  Myung-Hwan Kim (16)
  
  1. Center for Clinical Infectious Diseases, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0431, Japan
  2. Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA
  3. Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
  4. Section of Hepatobiliary and Pancreatic Surgery, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA
  5. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
  6. Clinical Research Center Kaken Hospital, International University of Health and Welfare, Ichikawa, Japan
  7. Department of Surgery, Toho University Medical Center Ohashi Hospital, Tokyo, Japan
  8. Department of Emergency and Critical Care Medicine, Ichinomiya Municipal Hospital, Ichinomiya, Japan
  9. Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan
  10. General Internal Medicine, Nagoya Daini Red Cross Hospital, Nagoya, Japan
  11. Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
  12. Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
  13. Department of Surgery, The University of Auckland, Auckland, New Zealand
  14. First Department of Surgery, Agia Olga Hospital, Athens, Greece
  15. Hepatobiliary and Pancreatic Surgery, Nexus Surgical Associates, Mount Elizabeth Hospital, Singapore, Singapore
  16. Department of Internal Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
  

文摘

Therapy with appropriate antimicrobial agents is an important component in the management of patients with acute cholangitis and/or acute cholecystitis. In the updated Tokyo Guidelines (TG13), we recommend antimicrobial agents that are suitable from a global perspective for management of these infections. These recommendations focus primarily on empirical therapy (presumptive therapy), provided before the infecting isolates are identified. Such therapy depends upon knowledge of both local microbial epidemiology and patient-specific factors that affect selection of appropriate agents. These patient-specific factors include prior contact with the health care system, and we separate community-acquired versus healthcare-associated infections because of the higher risk of resistance in the latter. Selection of agents for community-acquired infections is also recommended on the basis of severity (grades I–III). Free full-text articles and a mobile application of TG13 are available via http://www.jshbps.jp/en/guideline/tg13.html.